August 05, 2020
Article
Tisagenlecleucel, sold as Kymriah by Novartis, met its primary end point of complete response rate (CRR) in an interim analysis of a phase 2 study for relapsed or refractory follicular lymphoma (FL).
August 02, 2020
Article
A new treatment option is approved for patients with a common form of non-Hodgkin lymphoma who cannot have an autologous stem cell transplant.
July 31, 2020
Article
Understanding the patient point of view can help with treatment decisions as well as gauge the impact of treatment, the authors said.
July 31, 2020
Article
While immunoglobulin abnormalities appear to shorten treatment-free survival periods, they do not have an impact on overall survival in patients with chronic lymphocytic leukemia (CLL).
July 25, 2020
Article
The therapy, to be sold as Tecartus, will be used to treat adult patients with mantle cell lymphoma who have relapsed or not responded to other treatments.
July 24, 2020
Article
Experts surveyed regarding how best to treat patients with chronic lymphocytic leukemia (CLL) amid the pandemic agreed with social distancing, but were cautious about universal testing and treatment continuation.
July 18, 2020
Article
Older patients with chronic lymphocytic leukemia (CLL) appear to be more likely to have severe symptoms if they contract coronavirus disease 2019, according to new research.
July 18, 2020
Article
A new analysis of nearly 3 decades of data suggests leukemia rates are falling, except for 2 specific types.
July 08, 2020
Article
FDA has lifted a partial clinical hold on a phase 2 trial of a treatment for patients with relapsed or refractory (R/R) Hodgkin lymphoma from ADC Therapeutics. The trial of camidanlumab tesirine (Cami), an antibody drug conjugate that binds to CD25, is evaluating the safety and efficacy of the therapy and is intended to support the submission of a Biologics License Application to the FDA.
July 03, 2020
Article
Immunotherapy and chimeric antigen receptor (CAR) T-cell therapy are new and important treatments revolutionizing care of some cancers; however, their side effects can be very different than what is seen in traditional approaches, such as chemotherapy.